A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

Published:2015-05 Issue:5 Volume:26 Page:894-901
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Blumenschein G.R.,Smit E.F.,Planchard D.,Kim D.-W.,Cadranel J.,De Pas T.,Dunphy F.,Udud K.,Ahn M.-J.,Hanna N.H.,Kim J.-H.,Mazieres J.,Kim S.-W.,Baas P.,Rappold E.,Redhu S.,Puski A.,Wu F.S.,Jänne P.A.

Funder

GlaxoSmithKline

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/26/5/894/13706190/mdv072.pdf

Reference28 articles.

1. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer;Gainor;Clin Cancer Res,2013

2. KRAS mutations in non-small cell lung cancer;Riely;Proc Am Thorac Soc,2009

3. Somatic mutations of signaling genes in non-small-cell lung cancer;Sanders;Cancer Genet Cytogenet,2010

4. KRAS gene mutations in lung cancer: particulars established and issues unresolved;Okudela;Pathol Int,2010

5. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis;Mascaux;Br J Cancer,2005

Cited by 286 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of ULK1/2 and KRAS^G12C controls tumor growth in preclinical models of lung cancer;ELIFE;2024

2. Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer;eLife;2024-08-30

3. Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer;eLife;2024-08-30

4. Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature;Supportive Care in Cancer;2024-08-23

5. MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer;Signal Transduction and Targeted Therapy;2024-08-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3